Home › Research › Treatments
Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)
Vissia Viglietta, John T. O'Gorman, Leslie J. Williams, Ying Tian, Alfred W. Sandrock, Rachelle Smith Doody, Stephen Salloway, Frederik Barkhof et al.. Neurology, 2016-04-05
Topic: Drug trials: efficacy and safety
N/A. ENGAGE and EMERGE are Phase 3 clinical trials designed to confirm the clinical efficacy and safety profile of aducanumab in individuals with Early AD. Study support: funded by Biogen
Key findings
- ENGAGE and EMERGE are Phase 3 clinical trials designed to confirm the clinical efficacy and safety profile of aducanumab in individuals with Early AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Evidence strengthHigh
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 28 of the 58 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 28 of the 58 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Viglietta, V., O'Gorman, J. T., Williams, L. J., Tian, Y., Sandrock, A. W., Doody, R. S., et al. (2016). Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003). Neurology. https://doi.org/10.1212/wnl.86.16_supplement.s1.003
Vancouver
Viglietta V, O'Gorman JT, Williams LJ, Tian Y, Sandrock AW, Doody RS, et al. Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003). Neurology. 2016. doi:10.1212/wnl.86.16_supplement.s1.003.
BibTeX
@article{viglietta2016-5b6a5200,
author = {Viglietta, Vissia and O'Gorman, John T. and Williams, Leslie J. and Tian, Ying and Sandrock, Alfred W. and Doody, Rachelle Smith and Salloway, Stephen and Barkhof, Frederik and others},
title = {{Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)}},
journal = {Neurology},
year = {2016},
doi = {10.1212/wnl.86.16_supplement.s1.003},
url = {https://doi.org/10.1212/wnl.86.16_supplement.s1.003}
}